Treatment of Isoniazid-Resistant Tuberculosis
For isoniazid-resistant, rifampicin-susceptible tuberculosis, treat with 6 months of rifampicin, ethambutol, pyrazinamide, and levofloxacin (REZFQ). This is the current WHO-recommended regimen and represents the most evidence-based approach to managing this increasingly common form of drug resistance 1.
Current Standard Regimen
The most recent guideline evidence (2024) establishes that isoniazid resistance without concurrent rifampicin resistance affects approximately 10.6% of all TB cases globally 1. The recommended treatment consists of:
- Rifampicin (daily throughout)
- Ethambutol (daily throughout)
- Pyrazinamide (daily throughout, though may be limited to first 2 months in noncavitary disease with low bacillary burden)
- Levofloxacin (a later-generation fluoroquinolone, daily throughout)
- Duration: 6 months total 1
This regimen showed increased likelihood of treatment success (adjusted OR: 2.8,95% CI: 1.1-7.3) compared to standard treatment without a fluoroquinolone 1. The addition of the fluoroquinolone is critical—it compensates for the loss of isoniazid's early bactericidal activity and prevents treatment failure.
Alternative Regimens When Fluoroquinolones Cannot Be Used
If fluoroquinolone resistance exists or the patient has contraindications to fluoroquinolones, use rifampicin, ethambutol, and pyrazinamide for 6 months 1. However, this recommendation is based on expert opinion rather than clinical trial evidence, so close monitoring is essential.
Older Regimen Options (When Resistance Known Before Treatment)
If isoniazid resistance is documented before starting treatment, an alternative approach from older guidelines involves:
- 2 months: Rifampicin + Pyrazinamide + Ethambutol + Streptomycin
- 7 months: Rifampicin + Ethambutol
- Total duration: 9 months 2
This regimen showed good results when fully supervised 2.
When Resistance Discovered After Treatment Started
If isoniazid resistance is discovered after initiating standard therapy:
- Stop isoniazid immediately
- Continue rifampicin (15 mg/kg) + ethambutol for minimum 12 months
- Add pyrazinamide for the first 2 months 2
This extended duration (12 months total) is necessary because you've already lost time on an ineffective regimen.
Critical Clinical Considerations
High-risk populations for isoniazid resistance include:
- Patients of Indian subcontinent or Black African ethnic origin (4-6% resistance rate) 2
- HIV-positive patients (fourfold increased risk of drug resistance) 2
- Previously treated patients (11.4% prevalence vs. 7.4% in new patients) 3
Ethambutol should be included as a fourth drug in the initial phase for these high-risk groups even when starting empiric therapy, precisely because of this isoniazid resistance risk 2.
Monitoring and Supervision
All treatment should be administered via directly observed therapy (DOT) throughout the entire course 2, 4. This is non-negotiable for drug-resistant TB—nonadherence is the primary cause of treatment failure and emergence of additional resistance 4.
Monitor response by:
- Clinical symptoms
- Sputum smears and cultures at 3 months—if still positive, suspect treatment failure or additional resistance 4
- Drug susceptibility testing should be performed on initial isolates from all newly diagnosed patients 5
Important Caveats
Do not use high-dose isoniazid in established isoniazid-resistant TB beyond the first 2 weeks of treatment—recent evidence shows no meaningful bactericidal activity after this point, even with low-level resistance 6. The utility of including isoniazid at any dose in confirmed isoniazid-resistant TB remains questionable.
Pyrazinamide and levofloxacin co-resistance is rare among isoniazid-resistant isolates (0-5.3% depending on region), which supports the rationale for the WHO regimen 3. However, if additional resistance is detected or highly suspected, individualized regimens with expert consultation become necessary 1.
Treatment success rates with appropriate regimens are high: 80-97% in various studies 7, 8. Fluoroquinolone-containing regimens show superior outcomes with no relapse or acquired rifampicin resistance in some cohorts 8.
The key principle: rifampicin must be protected by at least two other effective drugs throughout treatment to prevent the catastrophic development of multidrug-resistant TB 2, 4.